About Diffuse Bio
Diffuse Bio is a biotechnology company that develops generative AI systems for engineering novel and useful proteins with unprecedented control and accuracy. Founded by pioneers in generative AI for proteins, the company bridges the gap between AI research and biological reality through proprietary assay development and large-scale data generation. Diffuse Bio's platform enables the design of protein therapeutics in minutes on a laptop compared to weeks in a traditional lab setting. The company's core products include DiffuseSandbox for rapid AI binder design, RamaX Discovery for ultra-fast experimental binder screening, and RamaX Opt for affinity maturation and multi-objective sequence optimization. Their approach combines cutting-edge AI models with massive biological datasets, delivering one-shot precision designs that are performant on the first iteration without time-intensive lab-in-the-loop screens. The company has demonstrated the ability to achieve 10-1000x improvements in binding affinity within one week, while simultaneously optimizing for multiple objectives including sequence liability removal, humanization, and cross-species binding. Diffuse Bio serves pharmaceutical and biotechnology partners, accelerating protein discovery and development through validated AI-designed proteins. The company's research has been published in Nature and featured in major media outlets including The New York Times and NBC News.
Mission & Story
Mission
We believe generative AI powered by biological data at scale will revolutionize how protein therapeutics are designed – faster and more accurately than ever before.
Founding Story
Founded by the pioneers behind GenAI for proteins, the company was established by a multidisciplinary team of scientists and engineers who developed breakthrough diffusion models for protein structure and sequence generation.
Clinical Focus
Medical conditions and clinical areas addressed by Diffuse Bio.
Who It Serves
Milestones & Awards
Recent Milestones
Published case study in June 2026 demonstrating >1000x tighter binders in 1 week. Launched RamaX platform for ultra-fast binder screening. Released DSG-2mini and DiffuseSandbox with public access. Published ProxyTm for protein thermostability measurement at scale.
Awards & Recognition
Published in Nature, featured in The New York Times, NBC News, Medscape. Participated in Y Combinator program.
Key Partnerships
Social & Media
Latest Updates
.png)
End-to-End Design with DiffuseSandbox and RamaXSupport for scaled-up binder design on DiffuseSandbox.
Ultra-fast Binder Optimization with RamaX OptTo our knowledge, the fastest affinity maturation available.
ProxyTm: Protein Thermostability at ScaleA new way to measure thermostability.
>1000X Tighter Binders in 1 Week with RamaX OptA case study on sequence optimization.
Benchmarking Minibinder Library Screening in <2 Weeks with RamaXBenchmarking our minibinder discovery platform vs SPR.
Company Details
- Headquarters
- San Carlos, CA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 64 →
A2A Pharmaceuticals
AI-driven pharmaceutical company focused on discovering and developing novel drug candidates using computational biology and machine learning.
AbCellera
AbCellera uses AI and machine learning to discover and develop antibody-based therapeutics and vaccines.
Absci
Absci uses AI-powered computational biology and machine learning to accelerate drug discovery and optimize therapeutic proteins and antibodies.
Adaptyv Bio
11-50 employees
Adaptyv Bio operates the world's fastest protein validation lab, providing automated experimental testing services for AI-designed proteins. The company enables protein engineers to validate binding, expression, and thermostability of novel protein designs through a fully automated platform with 3-week turnaround times.
Aitia
Aitia is a drug discovery and development company leveraging AI and computational biology to identify novel therapeutic targets and accelerate drug development.
Anagenex
Anagenex is a biotechnology company focused on drug discovery and development. The company appears to operate in the pharmaceutical research space, though specific details about their technology platform, therapeutic areas, and target markets are not available from the provided content.
Aqemia
Aqemia is a drug discovery company advancing next-generation medicines using generative AI and deep physics. The company combines AI-augmented discovery with computational chemistry to develop novel therapeutics at scale.
Arctoris
51-200 employees
Arctoris is a Partnership Research Organisation (PRO) providing automated wet lab biology R&D and data generation services for biotech, techbio, and pharma companies through its Ulysses® robotic platform.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.